Journal of Clinical Endocrinology & Metabolism, Vol 80, 3715-3723, Copyright © 1995 by Endocrine Society

ARTICLES

Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy--a clinical research center study

E Vlachopapadopoulou, JJ Zachwieja, JM Gertner, D Manzione, DM Bier, DE Matthews and AE Slonim
Department of Pediatrics, New York Hospital-Cornell Medical Center, New York 10021, USA.

Muscle weakness and wasting in myotonic dystrophy (MyD) are believed to be due to a decrease in muscle protein synthesis, secondary to insulin resistance. A 4-month, randomized, double blind, placebo-controlled trial was undertaken to assess whether recombinant human insulin-like growth factor I (rhIGF-I) may overcome the insulin resistance. Patients received either 5 mg rhIGF-I (n = 7) or placebo (n = 9), sc, twice daily. Glucose metabolism was assessed by stable label iv glucose tolerance test, amino acid metabolism by L-[13C] leucine turnover, body composition by dual energy x-ray absorptiometry and N excretion, and muscle response by manual muscle strength and neuromuscular function. In the treated group, the insulin sensitivity index, insulin action, and glucose disposal all increased (P < 0.05). Leucine flux and leucine incorporation into protein increased (P < 0.05), and the rate of leucine oxidation to leucine turnover decreased (P < 0.05), findings indicative of increased protein synthesis. Body weight and lean body mass increased, whereas percent body fat decreased (P < 0.05). An increase in manual muscle strength of 0.42 +/- 0.30 (P < 0.02) and in neuromuscular function of 17.5 +/- 11.7 (P < 0.02) occurred in the four patients who received a rhIGF-I dose greater than 70 micrograms/kg, whereas a more modest response occurred in the three patients who received a dose less than 70 micrograms/kg. Two patients showed dramatic improvement. Long term rhIGF-I therapy appears to cause metabolic and muscle improvement in optimally treated MyD patients.

This article has been cited by other articles:

				G. Perseghin, M. Comola, P. Scifo, S. Benedini, F. De Cobelli, R. Lanzi, F. Costantino, G. Lattuada, A. Battezzati, A. Del Maschio, et al. Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1 Am. J. Clinical Nutrition, August 1, 2004; 80(2): 357 - 364. [Abstract] [Full Text] [PDF]

				P. Gregorevic, D. R. Plant, K. S. Leeding, L. A. Bach, and G. S. Lynch Improved Contractile Function of the mdx Dystrophic Mouse Diaphragm Muscle after Insulin-Like Growth Factor-I Administration Am. J. Pathol., December 1, 2002; 161(6): 2263 - 2272. [Abstract] [Full Text] [PDF]

				S. Sato, M. Nakamura, D. H. Cho, S. J. Tapscott, H. Ozaki, and K. Kawakami Identification of transcriptional targets for Six5: implication for the pathogenesis of myotonic dystrophy type 1 Hum. Mol. Genet., May 1, 2002; 11(9): 1045 - 1058. [Abstract] [Full Text] [PDF]

				D. Furling, A. Marette, and J. Puymirat Insulin-Like Growth Factor I Circumvents Defective Insulin Action in Human Myotonic Dystrophy Skeletal Muscle Cells Endocrinology, September 1, 1999; 140(9): 4244 - 4250. [Abstract] [Full Text]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]